Arcadia Pharmaceuticals Reports Q3 Revenue Growth and Raises DAYBUE Guidance
ACAD Acadia Pharmaceuticals Inc
$16.50 -22.28%
View chart & analysis → - 1Arcadia Pharmaceuticals recorded total revenue of $342 million in the third quarter.
- 2Arcadia Pharmaceuticals achieved 39% year-over-year growth in DAYBUE net sales in the third quarter.
- 3More than 50% of DAYBUE patients in the U.S. transitioned to the STIX formulation by the end of the third quarter.
So what's the key point?
Arcadia Pharmaceuticals recorded $342 million in third-quarter revenue. Company performance is improving as DAYBUE sales increase.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.